Largest study of BRCA1 and BRCA2 carriers refines cancer risk estimates in Asian population

A team of clinician-scientists and scientists from the University of Nottingham (Malaysia campus), National Cancer Centre Singapore (NCCS), Cancer Research Malaysia, Nanyang Technological University, Singapore (NTU Singapore), University of Malaya, University of Cambridge, A*STAR's Genome Institute of Singapore (GIS) and other institutions, have conducted the largest study done to date of BRCA1 and BRCA2 (BReast CAncer Gene 1 and 2) carriers in an Asian population and refined breast and ovarian cancer risk estimates for this population.

Related Keywords

Singapore ,Malaysia ,Cambridge ,Cambridgeshire ,United Kingdom ,Nanyang ,Henan ,China ,United States ,Nottingham ,Chinese ,Malaysian ,Malaya ,America ,Singaporean ,Joanne Ngeow ,Singapore Lee Kong Chian School Of Medicine ,National Comprehensive Cancer Network ,Lancet Regional Health ,University Of Malaya ,University Of Cambridge ,National Cancer Centre Singapore ,Singapore National Precision Medicine Programme ,Genome Institute Of Singapore ,Cancer Research Malaysia ,University Of Nottingham Malaysia ,Head Of The Cancer Genetics Service ,Nanyang Technological University ,National Precision Medicine Programme ,Malaysian Chinese ,Singaporean Chinese ,Malaysian Indians ,Singaporean Indians ,East Asians ,South Asians ,North America ,Co Senior Author ,Associate Professor ,Genomic Medicine ,Lee Kong Chian School ,Cancer Genetics Service ,Singapore Ministry ,National Medical Research Council ,Clinician Scientist Award ,